VEGF-B signaling enhances fatty acid uptake in the liver, driving hepatic steatosis in diabetic models.588 Additionally, VEGF-B has been identified in the subcutaneous white adipose tissue of NAFLD patients, emphasizing its translational relevance in human disease.589 Patients with NAFLD also exhibit elevated serum levels of angiogenic markers, including VEGF, sVEGFR1, and sVEGFR2, which correlate with hepatic fibrosis severity and may serve as biomarkers.584. This evidence concerns the gene VEGFB and metabolic dysfunction-associated steatotic liver disease.